Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

glofitamab-gxbm

View Patient Information
A bispecific monoclonal antibody, with potential antineoplastic activity. Glofitamab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, glofitamab-gxbm binds to both T cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CD20 x anti-CD3 bispecific monoclonal antibody RO7082859
anti-CD20/CD3 bispecific monoclonal antibody RO7082859
glofitamab
US brand name:Columvi
Code name:RO 7082859
RO7082859
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search